[ Tres Cantos, Spain; Geneva, Switzerland – March 6, 2008 ]
GlaxoSmithKline (GSK) and the not-for-profit organization, Drugs for Neglected Diseases initiative (DNDi), today announced a collaborative research effort targeting neglected tropical diseases which disproportionately affect the developing world.
[ Tres Cantos, Spain; Geneva, Switzerland – March 6, 2008 ]
[ Geneva, Switzerland – December 12, 2007 ]
The Drugs for Neglected Diseases initiative (DNDi) has received a USD 25.7 million grant from the Bill & Melinda Gates Foundation to research and develop new medicines to treat human African trypanosomiasis (HAT), also known as sleeping sickness, and visceral leishmaniasis (VL).
[ Geneva, Switzerland – November 5, 2007 ]
The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), has granted Drugs for Neglected Diseases initiative (DNDi) USD 2.3 million to be disbursed over 3 years for research and development that focuses on developing a low-cost formulation of amphotericin B to treat visceral leishmaniasis.
[Research Triangle Park, USA, and Geneva, Switzerland – November 1, 2007 ]
SCYNEXIS and Drugs for Neglected Diseases initiative (DNDi), have agreed to collaborate on vital drug discovery research and development of affordable and effective therapies for human African trypanosomiasis (also known as sleeping sickness), one of the most devastating diseases in sub-Saharan Africa.
[ Geneva – October 12, 2007 ]
The Drugs for Neglected Diseases initiative (DNDi), a non-profit, drug R&D partnership, announced the appointments of two new members of its executive team: Shing Chang joins as the new Director of Research and Development, and Jean-Pierre Paccaud will serve as Director of Business Development.
[ Bangalore and Geneva – October 11, 2007 ]
Advinus Therapeutics (P) Ltd. and Drugs for Neglected Diseases initiative (DNDi), a not-for-profit R&D organization based in Geneva, Switzerland, announced today that they have formed a collaboration for discovery and development of novel therapies for visceral leishmaniasis (kala azar), a fatal infectious disease of developing countries including India.
[ Geneva – July 13, 2007 ]
Along with 3 newly appointed members to its governance structures, the Drugs for Neglected Diseases initiative (DNDi) today announced the appointments of 2 new chairmen – Dr. Marcel Tanner as the new Chairman of the Board of Directors and Dr. Julio Urbina as the new Chairman of the Scientific Advisory Committee (SAC).
[ Paris – March 1st, 2007 ]
Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) announced today that ASAQ, the new fixed-dose combination of artesunate (AS) and amodiaquine (AQ), will soon be available throughout sub-Saharan Africa. ASAQ is the first drug developed by the FACT (Fixed-dose, Artemisinin-based Combination Therapy) partners, managed by DNDi in partnership with sanofi-aventis.
[ Paris, Geneva – June 14, 2006 ]
AFD (Agence Française de Développement) and DNDi (Drugs for Neglected Diseases initiative) finalised a partnership agreement today to support the development of two new drugs for malaria.
[Geneva – May 16, 2006 ]
The R&D Appeal launched in June 2005 by the Drugs for Neglected Diseases initiative (DNDi), its founding partners, Oxfam, and the BIOS initiative, urges governments to take greater leadership in R&D on neglected diseases.
[ Geneva, Switzerland – February 8, 2006 ]
At a public hearing held today at the European Parliament in Brussels, EU governments were called upon to ensure that public funding in research be primarily invested in meeting public needs and priorities, including specific health needs of populations in developing countries.
[ Bangkok – February 2nd, 2006 ]
One of the first medicines developed by Drugs for Neglected Diseases initiative (DNDi), fixed-dose artesunate-mefloquine will be easier to use and less expensive than current ACTs, but experts agree that action is needed to make sure the treatments reach patients.
[ December 14, 2005 ]
University of Mississippi , MMV, and DNDi Agree to Collaborate on the Development of Anti-Parasitic Drugs for Both Malaria and Leishmaniasis.
[ Washington , DC – December 11, 2005 ]
First medicines developed by Drugs for Neglected Diseases initiative (DNDi) will be easier to use and less expensive than current ACTs, but action is needed to make sure the treatments reach patients.
[ Delhi, India – October 4, 2005 ]
The Drugs for Neglected Diseases initiative (DNDi), a not-for-profit drug development initiative, is collaborating with the Central Drug Research Institute (CDRI) Lucknow to test their library of compounds for possible activity against parasites that cause deadly neglected diseases such as kala azar and sleeping sickness.
[Marseille, France – September 13, 20051300 CET ]
DNDi presents results of Phase III clinical trials at Marseille conference
[ Tokyo , Japan – July 15, 2005 ]
Today, Drugs for Neglected Diseases initiative (DNDi) signed an agreement to conduct a joint research project with the Kitasato Institute in Japan to find a treatment for human African trypanosomiasis (sleeping sickness), a disease that kills tens of thousands in Africa each year.
[ June 8, 2005 ]
Call to governments to provide significant and sustained support to bring essential new drugs, vaccines, and diagnostics to people suffering and dying from neglected diseases.
[ Paris, April 8, 2005 ]
A collaborative agreement between the DNDi Foundation and Sanofi-Aventis to develop a new, easy-to-use malaria drug at target price below one dollar.
[ Geneva – April 5, 2006 ]
DNDi welcomes the final report of the WHO’s Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH). The report clearly states that it is imperative for governments to set global health priorities and promote innovation to develop and deliver much-needed medicines, vaccines, and diagnostics adapted to the needs of the sick and neglected in developing countries.